ABSTRACT
Background Ruxolitinib, a Janus kinase (JAK)-1/JAK-2 inhibitor that reduces T-cell activation and proliferation leading to a potent anti-inflammatory effect, was recently approved to treat steroid-refractory acute graft-versus-host disease (aGvHD) and is under study for chronic GvHD (cGvHD). However, there are few reports on its use in pediatric and young adult patients with GvHD.
Methods We retrospectively report our single center experience with ruxolitinib in 15 patients aged 11-29 years: 5 patients with steroid refractory/steroid dependent aGvHD and 10 patients with cGvHD who had failed at least one systemic therapy.
Results In the aGvHD group, ruxolitinib led to an overall response rate (ORR) of 40% at day 28 and 80% with longer follow-up (complete response, CR 60%), with a median of 21 days (5-74) to achieve a response. In the cGvHD group (9 evaluable patients), we observed an ORR of 67% and a CR of 22%, with a median of 78 days (35-180) to achieve a response. Adverse events included cytopenias, gastrointestinal symptoms, infections, and an allergic reaction attributable to ruxolitinib.
Conclusions Overall, our results show that ruxolitinib is an effective salvage therapy for severe GvHD in pediatric and young adult patients. The toxicities noted warrant adequate antimicrobial prophylaxis and close monitoring of blood counts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the NIH (K08 HL151809 to MM) and St. Baldricks Foundation (Scholar Award to MM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Stanford University gave ethical approval for this work (IRB-53278).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST STATEMENT: All authors declare there are no conflicts of interest in relation to this work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors, pending appropriate approval for access to clinical data.
Abbreviations
- JAK
- Janus Kinase
- aGvHD
- Acute Graft-versus-Host Disease
- cGvHD
- Chronic Graft-versus-Host Disease
- ORR
- Overall Response Rate
- CR
- Complete Response
- HCT
- Hematopoietic Cell Transplantation
- SR
- Steroid-refractory
- SD
- Steroid dependence
- PR
- Partial Response
- GI
- Gastrointestinal
- NR
- No Response
- TF
- Treatment Failure